What is the treatment for hypercalcemia (elevated calcium levels)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The treatment of hypercalcemia with calcium levels of 13.4 mg/dL requires prompt intervention with hydration, bisphosphonates, denosumab, steroids, and/or calcitonin, with zoledronic acid being the preferred bisphosphonate option, as recommended by the NCCN MM Panel members 1.

Initial Management

Initial management includes aggressive intravenous fluid rehydration with normal saline to increase renal calcium excretion, followed by loop diuretics like furosemide after adequate hydration to enhance calcium elimination.

  • Aggressive hydration with normal saline at 200-300 mL/hour
  • Loop diuretics like furosemide 20-40 mg IV after adequate hydration

Bisphosphonate Therapy

Bisphosphonates are the mainstay of treatment, with zoledronic acid 4 mg IV over 15-30 minutes or pamidronate 60-90 mg IV over 2-4 hours being first-line options, as stated in the NCCN guidelines 1.

  • Zoledronic acid 4 mg IV over 15-30 minutes
  • Pamidronate 60-90 mg IV over 2-4 hours

Additional Treatment Options

Calcitonin 4-8 IU/kg SC every 12 hours can provide rapid but short-term calcium reduction while waiting for bisphosphonates to take effect. For malignancy-related hypercalcemia, denosumab 120 mg SC may be used, especially in renal impairment. Glucocorticoids like prednisone 40-60 mg daily are beneficial for vitamin D-mediated or hematologic malignancy cases.

  • Calcitonin 4-8 IU/kg SC every 12 hours
  • Denosumab 120 mg SC for malignancy-related hypercalcemia
  • Glucocorticoids like prednisone 40-60 mg daily for vitamin D-mediated or hematologic malignancy cases

Monitoring and Long-term Management

Monitoring includes serial calcium levels, renal function, and electrolytes, with particular attention to preventing hypokalemia and hypomagnesemia during treatment. Addressing the underlying cause, whether primary hyperparathyroidism, malignancy, or medication effects, is crucial for long-term management, as emphasized in the NCCN guidelines 1.

  • Serial calcium levels
  • Renal function
  • Electrolytes
  • Preventing hypokalemia and hypomagnesemia during treatment

From the FDA Drug Label

DOSAGE AND ADMINISTRATION Hypercalcemia of Malignancy Consideration should be given to the severity of as well as the symptoms of hypercalcemia. Vigorous saline hydration alone may be sufficient for treating mild, asymptomatic hypercalcemia. Overhydration should be avoided in patients who have potential for cardiac failure In hypercalcemia associated with hemotologic malignancies, the use of glucocorticoid therapy may be helpful. Moderate Hypercalcemia The recommended dose of pamidronate disodium in moderate hypercalcemia (corrected serum calcium* of approximately 12 to 13.5 mg/dL) is 60 to 90 mg given as a SINGLE-DOSE, intravenous infusion over 2 to 24 hours. Severe Hypercalcemia The recommended dose of pamidronate disodium in severe hypercalcemia (corrected serum calcium* >13.5 mg/dL) is 90 mg given as a SINGLE-DOSE, intravenous infusion over 2 to 24 hours.

The treatment of hypercalcemia 13.4 would be considered as moderate hypercalcemia.

  • The recommended dose of pamidronate disodium is 60 to 90 mg given as a SINGLE-DOSE, intravenous infusion over 2 to 24 hours 2.
  • Vigorous saline hydration should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment 2.
  • Overhydration should be avoided in patients who have potential for cardiac failure.
  • Glucocorticoid therapy may be helpful in hypercalcemia associated with hemotologic malignancies 2.

From the Research

Treatment of Hypercalcemia

The treatment of hypercalcemia depends on the severity and underlying cause of the condition.

  • For mild hypercalcemia, treatment may not be necessary, but monitoring of serum calcium levels is recommended 3.
  • For symptomatic or severe hypercalcemia, initial therapy consists of hydration and intravenous bisphosphonates, such as zoledronic acid or pamidronate 3, 4, 5.
  • In patients with kidney failure, denosumab and dialysis may be indicated 3, 6.
  • Glucocorticoids may be used as primary treatment when hypercalcemia is due to excessive intestinal calcium absorption (vitamin D intoxication, granulomatous disorders, some lymphomas) 3, 5.

Management of Severe Hypercalcemia

Severe hypercalcemia is a life-threatening condition that requires urgent management.

  • Saline hydration and intravenous bisphosphonates, such as zoledronic acid, are effective in reducing serum calcium levels 4.
  • Furosemide may be prescribed in patients with renal insufficiency or heart failure to prevent fluid overload, but its effect on calcium levels is limited 4, 5.
  • Calcitonin may be administered for the immediate short-term management of severe symptomatic hypercalcemia 5.

Special Considerations

In patients with hypercalcemia due to primary hyperparathyroidism, parathyroidectomy may be considered depending on age, serum calcium level, and kidney or skeletal involvement 3.

  • In patients with hypercalcemia of malignancy, the prognosis is poor, and treatment is focused on reducing serum calcium levels and managing symptoms 3, 5.
  • Renal replacement therapy with regional citrate anticoagulation may be effective in treating hypercalcemic crisis 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.